Menu
Reimbursement Help Reimbursement Help

ONE-ON-ONE SUPPORT FOR INSURANCE QUESTIONS AND CHALLENGES

With AkebiaCares, your patients will have a dedicated case manager with the knowledge and resources to help make understanding access to AURYXIA as easy as possible

Even Without Filling Out the AkebiaCares Application, Our Case Managers Still Offer a Variety of Services

  • Share reimbursement services offered
  • Handle questions about the AkebiaCares Application
  • Provide education about the Copay and Patient Assistance Programs
  • Research eligibility status for Low-Income Subsidies (LIS)
Download Application

After the Completed AkebiaCares Application Has Been Received, Your Patient's Dedicated Case Manager Can:

  • Share reimbursement services offered
  • Handle questions about the AkebiaCares Application
  • Provide education about the Copay and Patient Assistance Programs
  • Research eligibility status for Medicare and/or Low-Income Subsidies (LIS)
  • Verify patient benefits
  • Coordinate prior authorizations
  • Assist patients experiencing therapy interruption
  • Investigate options for patients with financial obstacles to AURYXIA therapy

Connect with an AkebiaCares Case Manager now at 855-686-8601

*If you have any questions about an application after it has been submitted to AkebiaCares, please call 855-686-8601.

CALLING AFTER HOURS?

Leave a message and our AkebiaCares experts will return your call by the next business day.

INDICATIONS

AURYXIA® (ferric citrate) is indicated for:

  • The control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis
  • The treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

WARNINGS AND PRECAUTIONS

  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

ADVERSE REACTIONS

The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Hyperphosphatemia in CKD on Dialysis: Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%)
  • Iron Deficiency Anemia in CKD Not on Dialysis: Discolored feces (22%), diarrhea (21%), constipation (18%), nausea (10%), abdominal pain (5%) and hyperkalemia (5%)

SPECIFIC POPULATIONS

  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information